乌骨藤提取物对四氯化碳致大鼠慢性肝损伤的保护作用
|
摘要
目的:探讨乌骨藤提取物对四氯化碳(CCl_4)致慢性肝损伤模型大鼠的保护作用。方法:50只SD大鼠随机分为空白对照组,模型组,乌骨藤低、中、高剂量(10,20,40 mg·kg~(-1))组。以CCl_4皮下注射每周2次制备慢性肝损伤模型。同时各给药组每天灌胃(ig)给药1次,连续6周。计算大鼠的肝脏和脾脏指数;检测血清ALT,AST和肝组织中SOD,MDA,GSH-Px和Hyp水平;HE染色法检测肝组织病理变化;ELISA法检测大鼠血清IL-2水平;流式细胞术检测大鼠外周血T淋巴细胞亚群(CD3~+,CD4~+,CD8~+)的变化情况。结果:给予不同剂量乌骨藤治疗慢性肝损伤模型大鼠后,大鼠肝脾指数、血清ALT,AST,MDA和Hyp水平均不同程度降低,SOD,GSH-Px,IL-2水平升高,升高或降低的差异均以乌骨藤高剂量组尤为显著(P<0.01,P<0.05);乌骨藤显著改善大鼠肝组织病理损伤;大鼠外周血CD3~+和CD4~+亚群细胞比例下降,CD8~+细胞比例上升,CD4~+/CD8~+比值降低。结论:乌骨藤提取物对CCl4诱导的大鼠慢性肝损伤有保护作用,作用可能与其平衡T淋巴细胞亚群,调节免疫功能有关。
Objective: To investigate the protective effects of Marsdeniatenacissima extract on CCl_4-induced chronic liver injury in rats. Methods: Fifty SD rats were randomly divided into the following groups: normal control group,model group,low-,middle-and high-dose M. tenacissima groups( 10,20,40 mg·kg~(-1)). CCl_4 was given to rats by subcutaneous injection to make liver injury model. At the same time,the treatment groups were intragastricly administered with M. tenacissima twice a week for six weeks. The liver and spleen indexes of rats were calculated. The activities of ALT,AST in serum and SOD,MDA,GSH-Px and Hyp in liver tissues were tested.Histopathology of liver was observed by HE staining. The level of IL-2 in serum was tested by ELISA. The T lymphocytes( CD3~+,CD4~+,CD8~+) in blood were detected by using flow cytometer. Results: Compared with the model group,M. tenacissima-treated groups showed decreases in the activities of ALT,AST,SOD,MDA,GSHPx and Hyp,and an increase in IL-2 level. Moreover,the pathological damage of liver tissue was obviously improvedby M. tenacissima. Furthermore,the proportions of CD3~+,CD4~+,CD4~+/CD8~+ were reduced,while that of CD8~+ cells was up-regulated. Conclusion: Marsdeniatenacissima extract has protective effect on CCl_4-induced chronic liver injury in rats,which might be associated with its regulation of immunological function by counterbalance the T lymphocyte subsets.
Objective: To investigate the protective effects of Marsdeniatenacissima extract on CCl_4-induced chronic liver injury in rats. Methods: Fifty SD rats were randomly divided into the following groups: normal control group,model group,low-,middle-and high-dose M. tenacissima groups( 10,20,40 mg·kg~(-1)). CCl_4 was given to rats by subcutaneous injection to make liver injury model. At the same time,the treatment groups were intragastricly administered with M. tenacissima twice a week for six weeks. The liver and spleen indexes of rats were calculated. The activities of ALT,AST in serum and SOD,MDA,GSH-Px and Hyp in liver tissues were tested.Histopathology of liver was observed by HE staining. The level of IL-2 in serum was tested by ELISA. The T lymphocytes( CD3~+,CD4~+,CD8~+) in blood were detected by using flow cytometer. Results: Compared with the model group,M. tenacissima-treated groups showed decreases in the activities of ALT,AST,SOD,MDA,GSHPx and Hyp,and an increase in IL-2 level. Moreover,the pathological damage of liver tissue was obviously improvedby M. tenacissima. Furthermore,the proportions of CD3~+,CD4~+,CD4~+/CD8~+ were reduced,while that of CD8~+ cells was up-regulated. Conclusion: Marsdeniatenacissima extract has protective effect on CCl_4-induced chronic liver injury in rats,which might be associated with its regulation of immunological function by counterbalance the T lymphocyte subsets.
引文
[1]董丹丹,严佑琴.不明原因肝功能异常248例临床分析[J].中西医结合肝病杂志,2016,26(4):226-227.
[2]苗榅晗.肿瘤药物致肝损伤的原因及预防对策[J].当代医学,2017,23(1):166-167.
[3]刘贵军,李全,于雷.富硒姬松茸对小鼠急性酒精性肝炎的保护作用及其机制[J].中医药信息,2016,33(5):15-16.
[4]李红,于慧杰,盛国光.刀豆蛋白A诱导的C57 BL/6J型的研究[J].中西医结合肝病杂志,2016,26(2):93-95.
[5]沈利君,周建设,李晓誉,等.乌骨藤总苷H的化学成分研究[J].中国药学杂志,2011,46(8):585-588.
[6]张锐,刘静,刘阳晨,等.乌骨藤制剂诱导人肝癌细胞Bel-7402凋亡的实验研究[J].现代肿瘤医学,2013,21(3):488-491.
[7]李延芳,廖文斌,马丽芳,等.通光散化学成分和药理活性的研究进展[J].时珍国医国药,2007,18(7):1761-1763.
[8]赵陆华,相秉仁,谭喜莹.高效毛细管电泳法测定乌骨藤药材及其制剂中绿原酸的含量[J].中国现代应用药学杂志,2008,25(2):152-154.
[9]余天奉.还原型谷胱甘肽治疗慢性病毒性肝炎合并酒精肝损伤的临床疗效观察[J].临床医学工程,2016,23(2):225-226.
[10]洪友志,黄记水,洪文聪,等.恩替卡韦治疗合并肺结核的慢性HBV携带者效果观察[J].2016,32(11):2088-2091.
[11]王卫彬,李咏茵,侯金林.慢性乙型肝炎患者抗病毒治疗过程中的免疫应答特点[J].临床肝胆病杂志,2016,32(10):1858-1862.
[12]SHEPARD CW,SIMARD EP,FINELLI L,et al.Hepatitis B virus infection:epidemiology and vaccination[J].Epidemiol Rev,2006,28:112-125.
[13]MOHAMADNEJAD M,ALEKZADEH R.Type B hepatitis[J].New Engl J Med,2004,350(26):2719.
[14]陈艳芳,冯霞,王若伦.依达拉奉致严重肝损伤及血小板减少[J].药物不良反应杂志,2015,17(4):300-301.
[15]黄海智,余远裕.药源性肝损伤临床分析[J].医药前沿,2015,5(8):123-124.
[16]陈苓丽,王鹏,羊波,等.中药治疗药物性肝损伤实验研究进展[J].浙江中西医结合杂志,2014,24(5):471-473.
[17]王玉敏,赵健.肝病中药用药探讨[J].河北中医,2015,27(5):752-762.
[18]杨梅,张航,赵琦,等.祛脂愈肝颗粒对非酒精性脂肪肝模型大鼠Th17细胞表达的影响[J].贵州医药,2015,39(7):592-594.
[19]刘蕊洁,叶永安,江锋,等.保肝降酶中药在慢性乙型肝炎治疗中的系统评价[J].中西医结合肝病杂志,2014,24(1):54-64.
[20]HAN SY,ZHOU N,ZHOU F,et al.Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes[J].J Ethnopharmacol,2014,151(1):210-217.
[21]IANCU RI,IANCU D,MURARESCU D,et al.Platelet functions in acute and chronic experimentally induced hepatopathia[J].Rev Med Chir Soc Med Nat Iasi,2010,114(4):1101-1106.
[22]蔡纲,黄平,李绍民.翻白草对CCl4所致慢性肝损伤大鼠肝组织中SOD,MDA,GSH水平的影响[J].黑龙江医药科学,2016,39(1):33-36.
[23]KKER Z,WALUBO A,DU PLESSIS JB.The role of the immune system in nevirapine-induced subclinical liver injury of a rat model[J].ISRN Pharm,2012,2012:932542.
[24]魏桂林,曾雪亮,黎晓.3'-大豆苷元磺酸钠抗四氯化碳诱导的慢性肝损伤免疫机制探讨[J].赣南医学院学报,2016,36(2):172-175.
[2]苗榅晗.肿瘤药物致肝损伤的原因及预防对策[J].当代医学,2017,23(1):166-167.
[3]刘贵军,李全,于雷.富硒姬松茸对小鼠急性酒精性肝炎的保护作用及其机制[J].中医药信息,2016,33(5):15-16.
[4]李红,于慧杰,盛国光.刀豆蛋白A诱导的C57 BL/6J型的研究[J].中西医结合肝病杂志,2016,26(2):93-95.
[5]沈利君,周建设,李晓誉,等.乌骨藤总苷H的化学成分研究[J].中国药学杂志,2011,46(8):585-588.
[6]张锐,刘静,刘阳晨,等.乌骨藤制剂诱导人肝癌细胞Bel-7402凋亡的实验研究[J].现代肿瘤医学,2013,21(3):488-491.
[7]李延芳,廖文斌,马丽芳,等.通光散化学成分和药理活性的研究进展[J].时珍国医国药,2007,18(7):1761-1763.
[8]赵陆华,相秉仁,谭喜莹.高效毛细管电泳法测定乌骨藤药材及其制剂中绿原酸的含量[J].中国现代应用药学杂志,2008,25(2):152-154.
[9]余天奉.还原型谷胱甘肽治疗慢性病毒性肝炎合并酒精肝损伤的临床疗效观察[J].临床医学工程,2016,23(2):225-226.
[10]洪友志,黄记水,洪文聪,等.恩替卡韦治疗合并肺结核的慢性HBV携带者效果观察[J].2016,32(11):2088-2091.
[11]王卫彬,李咏茵,侯金林.慢性乙型肝炎患者抗病毒治疗过程中的免疫应答特点[J].临床肝胆病杂志,2016,32(10):1858-1862.
[12]SHEPARD CW,SIMARD EP,FINELLI L,et al.Hepatitis B virus infection:epidemiology and vaccination[J].Epidemiol Rev,2006,28:112-125.
[13]MOHAMADNEJAD M,ALEKZADEH R.Type B hepatitis[J].New Engl J Med,2004,350(26):2719.
[14]陈艳芳,冯霞,王若伦.依达拉奉致严重肝损伤及血小板减少[J].药物不良反应杂志,2015,17(4):300-301.
[15]黄海智,余远裕.药源性肝损伤临床分析[J].医药前沿,2015,5(8):123-124.
[16]陈苓丽,王鹏,羊波,等.中药治疗药物性肝损伤实验研究进展[J].浙江中西医结合杂志,2014,24(5):471-473.
[17]王玉敏,赵健.肝病中药用药探讨[J].河北中医,2015,27(5):752-762.
[18]杨梅,张航,赵琦,等.祛脂愈肝颗粒对非酒精性脂肪肝模型大鼠Th17细胞表达的影响[J].贵州医药,2015,39(7):592-594.
[19]刘蕊洁,叶永安,江锋,等.保肝降酶中药在慢性乙型肝炎治疗中的系统评价[J].中西医结合肝病杂志,2014,24(1):54-64.
[20]HAN SY,ZHOU N,ZHOU F,et al.Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes[J].J Ethnopharmacol,2014,151(1):210-217.
[21]IANCU RI,IANCU D,MURARESCU D,et al.Platelet functions in acute and chronic experimentally induced hepatopathia[J].Rev Med Chir Soc Med Nat Iasi,2010,114(4):1101-1106.
[22]蔡纲,黄平,李绍民.翻白草对CCl4所致慢性肝损伤大鼠肝组织中SOD,MDA,GSH水平的影响[J].黑龙江医药科学,2016,39(1):33-36.
[23]KKER Z,WALUBO A,DU PLESSIS JB.The role of the immune system in nevirapine-induced subclinical liver injury of a rat model[J].ISRN Pharm,2012,2012:932542.
[24]魏桂林,曾雪亮,黎晓.3'-大豆苷元磺酸钠抗四氯化碳诱导的慢性肝损伤免疫机制探讨[J].赣南医学院学报,2016,36(2):172-175.